Evidence map›Paper›PMID 42698582›Full record

ArticleJournal of traditional and complementary medicine2026

A prospective clinical study on the effectiveness of

Huihui Zhang, Weihang Li, Die Hu, Wentao Hu, Ting Wang, Panling Xu, Ping Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huihui ZhangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Weihang LiOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Die HuAnhui University of Traditional Chinese Medicine, Hefei, 230038, China.
Wentao HuAnhui University of Traditional Chinese Medicine, Hefei, 230038, China.
Ting WangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Panling XuOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Ping LiOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Chemotherapy for colorectal cancer (CRC) frequently induces immune dysfunction, which can negatively affect patient prognosis. Experimental procedure: This prospective, randomized, controlled trial enrolled patients with CRC who completed chemotherapy between January 2021 and June 2024. Participants were randomized (1:4:1) to receive placebo (N = 33), PEG (N = 132), or thymalfasin (N = 33). Thymalfasin (1.6 mg subcutaneously twice weekly), PEG (15 g/day orally), or placebo was administered for 8 weeks. Primary outcomes included changes in peripheral blood immune cell subsets (CD4 Results and conclusion: The PEG group demonstrated significant increases in the proportions of CD4

Indexed as

Chemotherapy-induced immune dysfunctionColorectal cancerPhellinus igniarius decoctionRandomized controlled trialTh1/Th2 balance

Identifiers

PMID42698582
PMCPMC13541534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.